Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results
1. ZYBT's revenues decreased by 12% to RMB186.4 million in FY 2024. 2. Swine vaccine sales dropped significantly due to strategic realignment. 3. R&D investment maintained with focus on growing pet vaccine market. 4. Company received two Category I New Veterinary Drug Certificates. 5. Global market expansion is now a primary strategic focus for ZYBT.